Addex Therapeutics (ADXN) updates investors with interim financial 6-K

Rhea-AI Filing Summary

Addex Therapeutics Ltd (ADXN) filed a routine Form 6-K on 20 June 2025. The filing primarily serves two administrative purposes: (1) it makes available unaudited interim condensed consolidated financial statements, management’s discussion and analysis (MD&A), and a 19 June 2025 press release as Exhibits 99.1-99.3; and (2) it formally incorporates those exhibits by reference into the company’s existing shelf registration statement on Form F-3 (No. 333-255089) and employee share-plan registration statements on Form S-8 (Nos. 333-255124 and 333-272515).

The company re-iterates that investors should review the risk factors detailed in its Form 20-F for the year ended 31 December 2024, filed 15 May 2025, and cautions that forward-looking statements remain subject to those risks. No new financial metrics, guidance, or transactional announcements are included in this 6-K.

CEO Tim Dyer signed the report on behalf of the registrant.

Insights

Financial Analyst

TL;DR – Administrative 6-K; no new financial data, neutral impact.

This Form 6-K is largely procedural. By furnishing interim financials and MD&A as exhibits, Addex keeps U.S. investors current and ensures its shelf and employee-share registration statements remain up-to-date. Because the actual numbers are not included in the body of the filing, investors must review Exhibit 99.1 and 99.2 for any material changes. Absent those details, the 6-K neither signals positive catalysts nor negative surprises. The risk disclaimer simply references previously disclosed 20-F risk factors. Overall, the filing is best viewed as a compliance event with negligible valuation impact.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

June 2025

 

 

 

Commission File Number: 001-39179

 

 

 

Addex Therapeutics Ltd

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Chemin des Mines 9,
CH-1202 Geneva,

Switzerland

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 

 

 

INCORPORATION BY REFERENCE

 

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

RISK FACTORS

 

Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on May 15, 2025. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Addex Therapeutics Ltd
 	 
 	By:	/s/ Tim Dyer
 	 	Name:	Tim Dyer
Date: June 20, 2025	 	Title:	Chief Executive Officer

 

3

 

 

EXHIBIT INDEX

 

Exhibit No.	 	Description
Exhibit 99.1 :	 	Unaudited Interim Condensed Consolidated Financial Statements
Exhibit 99.2 :	 	Management's Discussion and Analysis of Financial Condition and Result of Operations
Exhibit 99.3 :	 	Press Release dated June 19, 2025

 

4

 

FAQ

What exhibits were attached to Addex Therapeutics’ (ADXN) Form 6-K filed on 20 June 2025?

Exhibit 99.1 – unaudited interim condensed consolidated financial statements; Exhibit 99.2 – MD&A; Exhibit 99.3 – press release dated 19 June 2025.

Are the 6-K exhibits incorporated into Addex’s existing registration statements?

Yes. Exhibits 99.1 and 99.2 are incorporated by reference into the company’s Form F-3 (No. 333-255089) and Forms S-8 (Nos. 333-255124 & 333-272515).

Which form does Addex Therapeutics use for its annual reports?

Addex files annual reports under Form 20-F.

Where can investors find current risk factors for Addex Therapeutics?

The company directs investors to the risk factors section in its Form 20-F for the year ended 31 December 2024, filed 15 May 2025.

Who signed the 6-K and on what date?

Chief Executive Officer Tim Dyer signed the report on 20 June 2025.